Keyword → RSP

FDA's Vinay Prasad to Exit Biologics Post in April, Sending Biotech Stocks Sharply Higher

The announced departure of Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, triggered a significant rally in biotech equities Monday, with uniQure surging more than 31% in premarket trading. Investors interpreted the news as a signal that the agency may adopt a more predictable and industry-friendly regulatory posture for vaccines, gene therapies, and rare disease treatments.

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Major CAR-T Cell Therapy Bet

Gilead Sciences announced Monday it will acquire Arcellx for $115 per share in cash plus a contingent value right of $5 per share, representing an implied equity value of $7.8 billion and an 87% premium to Arcellx's Friday closing price. The deal centers on anito-cel, an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma that has already received FDA acceptance of its Biologics License Application, with a regulatory decision expected by December 23, 2026.

Small-Cap Stocks Reach New Highs, Bolstered by Economic Optimism

Small-cap equities, as measured by the Russell 2000, climbed to fresh highs, outperforming major indexes as institutional investors rotated toward value and cyclicals amid positive economic data and strong earnings. The rhythm of sector leadership suggests investors are seeking diversified exposures beyond mega-cap technology names as 2026 unfolds.

Mutual Funds Increase Allocations to Midcap Stocks, Revealing Market Confidence Shifts

Institutional investors are reallocating positions toward midcap equities after extended performance in large caps. This development reflects growing confidence in valuation opportunities outside major tech and AI names.